| Intestinal microbiota-derived short-chain fatty acids regulation of immune cell IL-22 production and gut immunity W Yang, T Yu, X Huang, AJ Bilotta, L Xu, Y Lu, J Sun, F Pan, J Zhou, ... Nature communications 11 (1), 4457, 2020 | 587 | 2020 |
| Therapeutic potential of spirooxindoles as antiviral agents N Ye, H Chen, EA Wold, PY Shi, J Zhou ACS infectious diseases 2 (6), 382-392, 2016 | 371 | 2016 |
| NAAG peptidase inhibitors and their potential for diagnosis and therapy J Zhou, JH Neale, MG Pomper, AP Kozikowski Nature reviews Drug discovery 4 (12), 1015-1026, 2005 | 323 | 2005 |
| Broad spectrum antiviral agent niclosamide and its therapeutic potential J Xu, PY Shi, H Li, J Zhou ACS infectious diseases 6 (5), 909-915, 2020 | 313 | 2020 |
| Transcription factor STAT3 as a novel molecular target for cancer prevention A Xiong, Z Yang, Y Shen, J Zhou, Q Shen Cancers 6 (2), 926-957, 2014 | 305 | 2014 |
| Drug discovery targeting bromodomain-containing protein 4 Z Liu, P Wang, H Chen, EA Wold, B Tian, AR Brasier, J Zhou Journal of medicinal chemistry 60 (11), 4533-4558, 2017 | 269 | 2017 |
| Small molecule inhibitors targeting activator protein 1 (AP-1) miniperspective N Ye, Y Ding, C Wild, Q Shen, J Zhou Journal of medicinal chemistry 57 (16), 6930-6948, 2014 | 238 | 2014 |
| A novel EPAC-specific inhibitor suppresses pancreatic cancer cell migration and invasion M Almahariq, T Tsalkova, FC Mei, H Chen, J Zhou, SK Sastry, F Schwede, ... Molecular pharmacology 83 (1), 122-128, 2013 | 236 | 2013 |
| Direct activation of Bax protein for cancer therapy Z Liu, Y Ding, N Ye, C Wild, H Chen, J Zhou Medicinal research reviews 36 (2), 313-341, 2016 | 224 | 2016 |
| Molecular targeting therapies for neuroblastoma: Progress and challenges A Zafar, W Wang, G Liu, X Wang, W Xian, F McKeon, J Foster, J Zhou, ... Medicinal research reviews 41 (2), 961-1021, 2021 | 215 | 2021 |
| A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors J Zhou, C Gelot, C Pantelidou, A Li, H Yücel, RE Davis, A Färkkilä, ... Nature cancer 2 (6), 598-610, 2021 | 212 | 2021 |
| Norepinephrine transporter inhibitors and their therapeutic potential J Zhou Drugs of the Future 29 (12), 1235, 2004 | 207 | 2004 |
| Existing drugs as broad-spectrum and potent inhibitors for Zika virus by targeting NS2B-NS3 interaction Z Li, M Brecher, YQ Deng, J Zhang, S Sakamuru, B Liu, R Huang, ... Cell research 27 (8), 1046-1064, 2017 | 194 | 2017 |
| Discovery and development of natural product oridonin-inspired anticancer agents Y Ding, C Ding, N Ye, Z Liu, EA Wold, H Chen, C Wild, Q Shen, J Zhou European journal of medicinal chemistry 122, 102-117, 2016 | 162 | 2016 |
| NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR RT Olszewski, N Bukhari, J Zhou, AP Kozikowski, JT Wroblewski, ... Journal of neurochemistry 89 (4), 876-885, 2004 | 157 | 2004 |
| Evolution in medicinal chemistry of ursolic acid derivatives as anticancer agents H Chen, Y Gao, A Wang, X Zhou, Y Zheng, J Zhou European journal of medicinal chemistry 92, 648-655, 2015 | 149 | 2015 |
| HDAC inhibitor increases histone H3 acetylation and reduces microglia inflammatory response following traumatic brain injury in rats B Zhang, EJ West, KC Van, GG Gurkoff, J Zhou, XM Zhang, ... Brain research 1226, 181-191, 2008 | 147 | 2008 |
| Allosteric modulation of class A GPCRs: targets, agents, and emerging concepts EA Wold, J Chen, KA Cunningham, J Zhou Journal of medicinal chemistry 62 (1), 88-127, 2018 | 140 | 2018 |
| Evolutions in fragment-based drug design: the deconstruction–reconstruction approach H Chen, X Zhou, A Wang, Y Zheng, Y Gao, J Zhou Drug Discovery Today 20 (1), 105-113, 2015 | 137 | 2015 |
| Neil3 and NEIL1 DNA glycosylases remove oxidative damages from quadruplex DNA and exhibit preferences for lesions in the telomeric sequence context J Zhou, M Liu, AM Fleming, CJ Burrows, SS Wallace Journal of Biological Chemistry 288 (38), 27263-27272, 2013 | 131 | 2013 |
